Ultragenyx Pharmaceutical Inc.: Revision history

20 August 2022

• curprev 22:2522:25, 20 August 2022 95.149.241.133 talk 1,712 bytes +11 No edit summary undo

14 August 2022

• curprev 10:2310:23, 14 August 2022 109.180.50.163 talk 1,701 bytes +15 No edit summary undo

30 July 2022

• curprev 23:2823:28, 30 July 2022 >Chris 1,686 bytes +1,686 Created page with "Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme rep..."